Eligibility & Testing

Talk to your doctor about using the Oncotype DX Genomic Prostate Score (GPS) and whether it’s right for you. If your doctor orders the test, no additional procedures are needed—samples from your most recent biopsy will be analyzed to provide information on the aggressiveness of your tumor.

Is the test right for you?

You could be eligible for the Oncotype DX GPS test if you have:

icon Biopsy within 3 years

icon Not started treatment

icon Localized prostate cancer

Three simple steps to get the test

With your Genomic Prostate Score, you and your doctor will have the information you need to create a plan that is right for you.

Step1   

1. TEST

The Oncotype DX GPS test is conducted on a small tissue sample already taken from your most recent biopsy.
Step2   

2. RECEIVE

About 2 weeks after your biopsy arrives at the Exact Sciences laboratory, your GPS result will be available to your doctor. Your results will include your level of risk for prostate cancer death and metastasis within 10 years after surgery, as well as your risk for adverse pathology.*
Step3   

3. DISCUSS

You and your doctor can use your results to help understand your options and discuss what's next for you.

The Oncotype DX GPS test is covered by Medicare (for eligible patients with NCCN Very Low-, Low-, Intermediate-, and High-risk prostate cancer). Private insurance coverage varies.

NCCN® very low-, low-, intermediate, or high-risk prostate cancer means1:

  • Your blood levels of prostate-specific antigen (PSA), a protein produced in the prostate gland, are less than 20 ng/mL.
  • Your Gleason score, an estimate of prostate cancer aggressiveness based on how the cancer looks under a microscope, is 4+3 or below.
  • The stage of your tumor is T1c or any T2.
  • Any ONE of the following: T3a, OR Grade Group 4 or Grade Group 5, OR PSA >20 ng/mL.

If you don’t know these numbers or are not sure, ask your doctor, or request a copy of your pathology report.

REFERENCES

* Adverse pathology will not be reported for Gleason 4+3 patients due to the aggressive nature of their disease.

1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.1.2021.

National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Making cancer care smarter.®
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.